Heyu Biological Technology (OTCMKTS:HYBT – Get Free Report) and Zynex (NASDAQ:ZYXI – Get Free Report) are both small cap Computer and Technology companies, but which business is the better one? We compare the two businesses based on risk, revenue, analyst recommendations, valuation, profitability, dividends and strength of institutional holdings.
Profitability
This table compares the net profit margins, return on equity, and return on assets of Heyu Biological Technology and Zynex.
Net profit margin Return on equity Return on total assets Heyu Biological Technology -453.55% -6.43% -4.43% Zynex 3.12% 14.15% 4.50%
Institutional and insider ownership
29.7% of Zynex's shares are held by institutional investors. 89.2% of Heyu Biological Technology's shares are owned by insiders. In comparison, 52.1% of Zynex's shares are owned by insiders. A high level of institutional ownership suggests that large asset managers, endowments and hedge funds believe that the company will outperform the market in the long term.
Revenue and Ratings
This table compares the revenue, earnings per share, and valuation of Heyu Biological Technology and Zynex. Total Revenue Price to Earnings Ratio Net Income Earnings per Share Price to Earnings Ratio Heyu Biological Technology $80,000.00 322.65 -$270,000.00 N/AN/A Zynex $193.61 million 1.25 $9.73 million $0.23 33.00
Zynex's revenue and profits are higher than Heyu Biological Technology's.
Analysts' comments
Here's a summary of Heyu Biological Technology and Zynex's current ratings provided by MarketBeat.com.
Sell Rating Hold Rating Buy Rating Strong Buy Rating Rating Score Heyu Biological Technology 0 0 0 0 N/A Zynex 0 0 2 0 3.00
The consensus price target for Zynex is $14.00, suggesting an upside potential of 84.45%. Given Zynex's higher upside potential, analysts clearly consider it a better buy than Heyu Biological Technology.
Risk and Volatility
Heyu Biological Technology's beta is -17.74, indicating that the company's stock price is 1,874% less volatile than the S&P 500. In comparison, Zynex's beta is 0.53, indicating that the company's stock price is 47% less volatile than the S&P 500.
summary
Comparing the two stocks, Zynex outperforms Heyu Biological Technology in 9 out of 11 factors.
About Heyu Biological Technology
(Get your free report)
Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.
About Zynex
(Get your free report)
Zynex, Inc., together with its subsidiaries, designs, manufactures and markets medical devices to treat chronic and acute pain and rehabilitate by activating and exercising muscles with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device, NeuroMove, an electromyography and electrical stimulation technology device, InWave, an electrical stimulation product for treating female urinary incontinence, E-Wave, a NMES device, and M-Wave, a NMES device, which are sold by field sales representatives to physicians and therapists. The company also supplies private label products, including electrodes to deliver electrical current to the body and batteries for use in electrotherapy products. In addition, the company markets Comfortrac/Saunders for cervical traction, JetStream for heat/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Additionally, the company offers the Zynex Fluid Monitoring System (CM-1500), the Zynex Wireless Fluid Monitoring System (CM-1600), which are noninvasive monitoring devices designed to measure relative changes in bodily fluid volume in adult patients, the NiCO CO-Oximeter, a laser-based noninvasive co-oximeter, and the HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company offers products used for pain management and control, stroke and spinal cord injury rehabilitation, hemodynamic and intravascular volume monitoring, and pulse oximetry monitoring. The company sells its products primarily in the United States through its direct sales force. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Get Heyu Biological Technology News and Ratings Daily – Enter your email address below to receive a concise summary of the latest news and analyst ratings on Heyu Biological Technology and related companies every day with MarketBeat.com's free daily email newsletter.
